Bacterial Vaginosis (BV) and Trichomoniasis are among the most common Sexually Transmitted Diseases (STD). Both are treatable with metronidazole, but recurrences are frequent. Simple, presumptive screening tests are not available and diagnoses are often made on the basis of subjective clinical findings. Recent associations of BV with placental infection and premature delivery and the associations of Trichomoniasis with increases in septicemia, premature membrane rupture, and episiotomy infection has increased the need for Rapid, Accurate, Cost-Effective, Simple (RACES- format) on-site diagnostic tests for these disease. In Phase I, Litmus Concepts, Inc. (LCI) demonstrated the technical feasibility of developing a simple, inexpensive, colorimetric test panel to provide clinicians with objective, on-site data to assist with the presumptive diagnosis of these disorders. During its Phase II efforts, LCI will conduct the research needed to incorporate its proprietary technology into a new metabolic screening panel for presumptive diagnosis of infectious vaginitis. Such a screening panel will permit standardization of various testing procedures and produce uniform test results, thereby allowing comparison of clinical study data.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AI028148-03
Application #
2064271
Study Section
Special Emphasis Panel (SSS (B1))
Project Start
1990-05-01
Project End
1992-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Litmus Concepts, Inc.
Department
Type
DUNS #
City
Santa Clara
State
CA
Country
United States
Zip Code
95051
Mestecky, Jiri; Nguyen, Huan; Czerkinsky, Cecil et al. (2008) Oral immunization: an update. Curr Opin Gastroenterol 24:713-9
Menge, A C; Mestecky, J (1993) Surface expression of secretory component and HLA class II DR antigen on glandular epithelial cells from human endometrium and two endometrial adenocarcinoma cell lines. J Clin Immunol 13:259-64